Scoping the international impact from four independent national dermatology trials

Do open-access dermatology articles have higher citation counts than those with subscription-based access?

BACKGROUND

Open-access (OA) publishing is increasingly prevalent in dermatology, and many journals now offer hybrid options, including conventional (subscription-based access [SA]) publishing or OA (with an author publishing charge) in a subscription journal. OA publishing has been noted in many disciplines, but this has been rarely studied in dermatology.

METHODS

Using the Clarivate Journal Citation Report, we compiled a list of English-language dermatology hybrid OA journals containing more than 5% OA articles. We sampled any OA review or original research article in 4 issues from 2018 to 2019 and matched an equal number of SA articles. Citation count, citation count excluding self-citations and view counts found using Scopus and Altmetrics score were recorded for each article. Statistical analyses were performed using logistic and negative binomial models using R software.

RESULTS

Twenty-seven hybrid dermatology journals were found, and 538 articles were sampled (269 OA, 269 SA). For both original research and review articles, OA articles had significantly higher mean citation counts (mean 13.2, standard deviation [SD] 17.0) compared to SA articles (mean 7.9, SD 8.8) (odds ratio [OR] 1.04; 95% CI 1.02-1.05; P < .001) including when adjusted for time from publication. Original research OA articles had significantly higher citation counts than original research SA articles (excluding self-citations; OR, 1.03; 95% CI, 1.01-1.05; P = .003), and review articles also had OA citation advantage than review SA articles (OR, 1.06; 95% CI, 1.02-1.11; P = .008). There was, however, no significant difference in citation counts between review articles and original research articles (OR, 1.00; 95% CI, 0.19-5.31; P = 1.000). There was no significant difference seen in view counts (OA: mean±SD 17.7±10.8; SA: mean±SD 17.1±12.4) and Altmetric score (OA: mean±SD 13.2±47.8; SA: mean±SD 6.3±25.0) between OA and SA articles. Potential confounders included the fact that more OA articles were published in Europe than in Asia, and pharmaceutical-funded articles were more likely to be published OA.

CONCLUSIONS

We noted a higher citation count for OA articles than SA articles in dermatology hybrid journals. However, dermatology researchers should take into account confounding factors when deciding whether to increase the impact of their work by selecting OA over SA publishing.

Celebrating 20 years of the UK Dermatology Clinical Trials Network: Part 1 – developing and delivering high quality independent clinical trials

The UK Dermatology Clinical Trials Network (UK DCTN) was formed in 2002 with the aim of developing and supporting high‐quality independent national clinical trials that address prioritized research questions for people with skin disease. Its philosophy is to democratize UK dermatological clinical research and to tackle important clinical questions that industry has no incentive to answer. The network also plays a key role in training and capacity development. Its membership of over 1000 individuals includes dermatology consultants, trainees, dermatology nurses, general practitioners, methodologists and patients. Its organizational structures are lean and include a co‐ordinating team based at the Centre of Evidence‐Based Dermatology in Nottingham, and an executive with independent members to ensure probity and business progression. A prioritization panel and steering group enable a pipeline of projects to be prioritized and refined for external funding from independent sources. The UK DCTN has supported and completed 12 national clinical trials, attracting investment of over £15 million into UK clinical dermatology research. Trials have covered a range of interventions from drugs such as doxycycline (BLISTER), silk clothing for eczema (CLOTHES) and surgical interventions for hidradenitis suppurativa (THESEUS). Trial results are published in prestigious journals and have global impact. Genuine partnership with patients and carers has been a strong feature of the network since its inception. The UK DCTN is proud of its first 20 years of collaborative work, and aims to remain at the forefront of independent dermatological health technology assessment, as well as expanding into areas including diagnostics, artificial intelligence, efficient studies and innovative designs.